Dr. Hamid Emamekhoo, MD
Claim this profileUniversity of Wisconsin Carbone Cancer Center
Area of expertise
Prostate Cancer
Hamid Emamekhoo, MD has run 7 trials for Prostate Cancer. Some of their research focus areas include:
Lung Cancer
Hamid Emamekhoo, MD has run 3 trials for Lung Cancer. Some of their research focus areas include:
Affiliated Hospitals
University Of Wisconsin - Carbone Cancer Center
University Of Wisconsin
Clinical Trials Hamid Emamekhoo, MD is currently running
Registry
for Advanced Prostate Cancer
Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 CRPC. The goal is to establish a population-based registry and recruit patients across academic and community practices from Australia, Barbados, Brazil, Canada, Ireland, Jamaica, Kenya, Nigeria, Norway, Spain, South Africa, Sweden, Switzerland, the United Kingdom (UK), and the United States (US). Target accrual number and number of participating sites are subject to change based on accrual, funding, and interest in participation by other international sites. This cohort study will facilitate a better understanding of the variation in care and treatment of advanced prostate cancer across countries and across academia and community based practices. Detailed data will be collected from patients at study enrollment and then during follow-up, for a minimum of five years. Patients will be followed prospectively for overall survival, clinically significant adverse events, comorbidities, changes in cancer treatments, and PROMs. PROMs questionnaires will be collected at enrollment and every three months thereafter. Physician Questionnaires will be collected from all participating sites at patient enrollment, time of first change in treatment and/or one year follow-up, at each subsequent change of treatment, and discontinuation of treatment. As such, this registry will help identify the treatment sequences or combinations that optimize overall survival and PROMs for men with mHSPC and M0/M1 CRPC. By collecting blood at enrollment, time of first change in treatment and/or one year follow-up (plasma, cell free DNA, buffy coat / RNA), this registry will further identify and validate molecular phenotypes of disease that predict response and resistance to specific therapeutics. Additionally, every effort will be made to collect blood specimen at each subsequent change in treatment due to progression of disease. When feasible, existing tumor tissue may be collected for correlation with described blood based studies. All samples will be used for future research. This cohort study will provide the research community with a unique biorepository to identify biomarkers of treatment response and resistance.
Recruiting
1 award
N/A
5 criteria
Stereotactic Radiation + Immunotherapy
for Kidney Cancer
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread from where it first started (primary site) to other places in the body (metastatic). Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses of radiation over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, avelumab, and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib, cabozantinib, and lenvatinib are in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving SABR in combination with standard of care immunotherapy may help shrink or stabilize the cancer in patients with renal cell cancer.
Recruiting
1 award
Phase 2
21 criteria
More about Hamid Emamekhoo, MD
Clinical Trial Related
8 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Hamid Emamekhoo, MD has experience with
- Nivolumab
- Ipilimumab
- Cabozantinib
- PTVG-HP
- Docetaxel
- Androgen Deprivation Therapy
Breakdown of trials Hamid Emamekhoo, MD has run
Prostate Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Hamid Emamekhoo, MD specialize in?
Hamid Emamekhoo, MD focuses on Prostate Cancer and Lung Cancer. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are DDRD negative.
Is Hamid Emamekhoo, MD currently recruiting for clinical trials?
Yes, Hamid Emamekhoo, MD is currently recruiting for 2 clinical trials in Madison Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that Hamid Emamekhoo, MD has studied deeply?
Yes, Hamid Emamekhoo, MD has studied treatments such as Nivolumab, Ipilimumab, Cabozantinib.
What is the best way to schedule an appointment with Hamid Emamekhoo, MD?
Apply for one of the trials that Hamid Emamekhoo, MD is conducting.
What is the office address of Hamid Emamekhoo, MD?
The office of Hamid Emamekhoo, MD is located at: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin 53705 United States. This is the address for their practice at the University of Wisconsin Carbone Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.